Abstract: Disclosed is a method of treatment for anti-Alzheimer's disease based on an action mechanism associated with amyloid ? protein, which action mechanism is different from conventional action mechanisms. The treatment Alzheimer's disease uses a therapeutic agent for cognitive impairment induced by amyloid ? protein, which therapeutic agent comprises a peptide having the amino acid sequence represented by SEQ ID NO:1 or a peptide similar to this peptide, especially a peptide containing the amino acid sequence represented by SEQ ID NO:2, which is a partial sequence of SEQ ID NO:1.

Abstract: A laryngeal mask is provided with an outer tube and a connector, having a base end in which is formed a first connecting portion capable of being connected to an artificial respirator and a leading end in which is formed a ventilation opening, the outer tube and the connector having a communication passage formed therein that communicates between the first connecting portion and the ventilation opening, a ring-shaped cuff capable of tightly adhering to a tracheal opening of a patient trachea as a result of inflating in a state where the ring-shaped cuff is inserted to a predetermined insertion position, and hyoid bone-contacting portions and protruding laterally from the outer tube so as to contact from above a site in a pharyngeal portion of the patient corresponding to a hyoid bone of the patient in a state where the ring-shaped cuff is inserted to the insertion position.

Abstract: The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate dehydrogenase inhibitor of the invention contains a compound represented by formula (III); i.e., isosafrole or a compound having isosafrole as a scaffold, and the antiepileptic drug of the invention has these compounds as an active ingredient.

Abstract: The invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INF?, and IFN?. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug.

Abstract: There is provided an oral biofilm inhibitor having an exceptional inhibitory effect on oral biofilm formation. It is an oral biofilm inhibitor comprising a curable composition containing an antimicrobial agent, wherein a compressive strength of a cured product formed by curing the composition is 150 MPa or less, and a content of the antimicrobial agent is 0.001 to 3% by weight. An oral biofilm inhibitor thus obtained is used for inhibiting biofilm formation in an oral cavity by applying a curable composition containing an antimicrobial agent to a dental defect site for allowing the composition to cure at the dental defect site, and then disintegrating the cured composition.

Abstract: The present invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INF?, and IFN?. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug.

Abstract: There is provided a lysine oligomer derivative, wherein an ?-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an ?-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.

Abstract: A liquid mixture obtained by mixing a bolus and an adjusting agent is poured into a tray-shaped container, and during spreading of bolus particles constituting the bolus along the bottom surface, the tray-shaped container is placed in a first inclined state in which the bottom surface is inclined by increasing the height of one edge side in the left-right direction of the tray-shaped container relative to the other edge side thereof, and the liquid mixture in the tray-shaped container is moved toward the other edge side, after which the tray-shaped container is placed in a second inclined state in which the bottom surface is inclined in the reverse direction by reducing the height of one edge side of the tray-shaped container relative to the other edge side thereof, after which the bottom surface is placed in a horizontal state, and the bolus particles are thereby spread.

Abstract: An object of the present invention is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus to replicate specifically in a cancer cell and express REIC protein or REIC C domain protein, wherein the conditionally replicating adenovirus is obtained by inserting full-length REIC DNA or REIC C domain DNA into a conditionally replicating adenovirus comprising an ITR (inverted terminal repeat) sequence of an adenovirus type 5 genome and insertion of an HRE sequence, an hTERT promoter, a decorin-encoding DNA, and a DNA encoding a peptide comprising an RGD sequence.

Abstract: A dental diagnosis device has an occlusion sound detection member that detects occlusion sounds by teeth and an analysis member that analyzes the teeth occlusion based on detected occlusion sounds by the occlusion detection member. The occlusion detection member comprises a sucker shaped suction member that sticks to a tooth, a hollow passage connected to a through-hole installed in the suction member and it is operably controlled to appropriate negative pressure by which the suction member is adhered to a tooth, and a detection member connected to the suction member, which detects occlusion sound via the suction member.

Abstract: The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.

Abstract: A termite extermination method of the present invention includes putting a termite extermination device 1 at a termite habitat. The termite extermination device 1 includes an exterminating agent housing 3 that is at least partially formed of a moisture-proof film 12 and houses an exterminating agent 13 in an interior of the exterminating agent housing 3. The moisture-proof film 12 includes a laminate having a paper layer and a metal layer laminated one upon another. At least the paper layer is subjected to a rugging process. The laminate is disposed in the exterminating agent housing 3 so that the paper layer serves as an outermost surface.

Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.

Abstract: There is provided a method for producing an artificial retina in which an organic dye compound that induces a receptor potential responding to photostimulation is fixed on a polymer sheet substrate, comprising a bonding step of immersing the substrate in a solution containing the organic dye compound to chemically bond the organic dye compound to the substrate; a first washing step of washing with water the substrate to which the organic dye compound has been chemically bonded; and a second washing step of, after the first washing step, washing with an organic solvent the substrate to which the organic dye compound has been chemically bonded. Thus, there can be provided an artificial retina which has excellent mechanical properties such as elongation at break and good biocompatibility, and is capable of inducing a receptor potential responding to photostimulation with high sensitivity.

Abstract: The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X.

Abstract: This invention relates to an anode active material comprising at least one iron oxide selected from the group consisting of amorphous iron oxides, ferrihydrite, and lepidocrocite. The invention also relates to a lithium ion secondary battery anode material comprising the anode active material as a constituent component, a lithium ion secondary battery anode comprising the lithium ion secondary battery anode material, and a lithium ion secondary battery comprising the lithium ion secondary battery anode.

Abstract: The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X.

Abstract: Provided is a catalyst for producing hydrogen, which catalyst has higher performance than conventional catalysts since, for example, it exhibits a certain high level of activity in an aqueous formic acid solution at high concentration even without addition of a solvent, amine and/or the like. The metal phosphine complex is a metal phosphine complex represented by General Formula (1): MHm(CO)Ln, wherein M represents an iridium, iron, rhodium or ruthenium atom; in cases where M is an iridium or rhodium atom, m=3 and n=2, and in cases where M is an iron or ruthenium atom, m=2 and n=3; and the number n of Ls each independently represent a tri-substituted phosphine represented by General Formula (2): PR1R2R3. The catalyst for producing hydrogen comprises the metal phosphine complex as a constituent component.

Abstract: The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.

Abstract: [Problem] The present invention addresses the problem of providing a compound that is useful for preventing or treating diseases associated with malfunctioning of PGI2 receptors, in particular, pulmonary hypertension. [Solution] A positive allosteric regulator of a PGI2 receptor which comprises a compound represented by formula (1) or a pharmaceutically acceptable salt, hydrate or solvate thereof. (1) (In the formula, R1 is a branched chain or cyclic alkyl or alkenyl having 3 to 10 carbon atoms which may be substituted, R2 is a hydrogen atom or an alkyl having 1 to 6 carbon atoms which may be substituted, R3 is 1 to 4 substituents which are the same or different independently selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl having 1 to 6 carbon atoms which may be substituted, and an alkoxy having 1 to 6 carbon atoms which may be substituted, and A is an aryl which may be substituted or a heteroaryl which may be substituted.